139110-80-8
139110-80-8 structure
- Name: Zanamivir
- Chemical Name: zanamivir
- CAS Number: 139110-80-8
- Molecular Formula: C12H20N4O7
- Molecular Weight: 332.310
- Catalog: API Antibiotics Other antibiotics
- Create Date: 2018-02-05 08:00:00
- Modify Date: 2026-07-03 10:24:14
-
Zanamivir is an influenza viral neuraminidase inhibitor with IC50 values of 0.95 nM and 2.7 nM for influenza A and B, respectively.
| Name | zanamivir |
|---|---|
| Synonyms |
Zanamivir Impurity A
Zanamivir Impurities Zanamivir monohydrate, >= 139-6 5-(acetylamino)-4-{[amino(imino)methyl]amino}-2,6-anhydro-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonic acid (2R,3R,4S)-4-Guanidino-3-(prop-1-en-2-ylamino)-2-((1R,2R)-1,2,3-trihydroxypropyl)-3,4-dihydro-2H-pyran-6-cboxylic acid 5-(Acetylamino)-4-[(aminoiminomethyl)amino]-2,6-anhydro- 3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonic Acid Zanamavir Zanamivir Hydrate 5-Acetamido-2,6-anhydro-4-carbamimidamido-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonic acid 5-(AcetylaMino)-4-[(aMinoiMinoMethyl)amino]-2,6-anhydro- 3,4,5-trideoxy (4S,5R,6R)-5-acetamido-4-(diaminomethylideneamino)-6-[(1S,2R)-1,2,3-trihydroxypropyl]-5,6-dihydro-4H-pyran-2-cboxylic acid GANA Relenza 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid Zanamivir hydrate CRS Zamivir Zanamivir for assay CRS anaMivir Hydrate(Relenza) Zanamivir for assay 121167X (2R,3R,4S)-3-Acetamido-4-(diaminomethylideneamino)-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-cboxylic acid 3-acetamido-4-(diaminomethylideneamino)-2-(1,2,3-trihydroxypropyl)-3,4-dihydro-2H-pyran-6-cboxylic acid hydrate Zanamivir solution,100ppm ZANAMIVIR HYDRATE //BP ZANAMIVIR HYDRATE D-glycero-D-galacto-Non-2-enonic acid, 5-(acetylamino)-4-[(aminoiminomethyl)amino]-2,6-anhydro-3,4,5-trideoxy- (9CI) ZanaMivir Hydrate(Relenza) (6R)-5-Acetamido-2,6-anhydro-4-carbamimidamido-3,4,5-trideoxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]-L-threo-hex-2-enonic acid Zanamivir (GG-167) Hsdb (2R,3R,4S)-3-Acetamido-4-guanidino-2-((1R,2R)-1,2,3-trihydroxypropyl)-3,4-dihydro-2H-pyran-6-cboxylic acid Zanamivir& intermediates ANAMIVIR HYDRATE Zanamivir, Antiviral agent 5-(Acetylamino)-4-[(aminoiminomethyl)amino]-2,6-anhydro-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonic Acid 5-Acetamido-2,6-anhydro-3,4,5-trideoxy-4-guanidino-D-glycero-D-galacto-non-2-enonic acid 5-(acetylamino)-2,6-anhydro-4-carbamimidamido-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonic acid 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid 4-Guanidino-Neu5Ac2en Zanamivirsesquihydrate Zanamivir Impurity Valproic Acid Impurity 47 Sodium salt Zanamivir for system suitability GG 167 Zanamir 4-Guanidino-Neu5Ac2en GANA (inhibitor) ZANAMIVIR(FORR&DONLY) 5-Acetamido-4-guanidino-2,3,4,5-tetradeoxy-D-glycero-D-galacto-non-2-enopyranosonic Acid ZanamivirQ: What is Zanamivir Q: What is the CAS Number of Zanamivir Q: What is the storage condition of Zanamivir Q: What e the applications of Zanamivir Unii-L6o3xi777i Zanamivir, 10 mM in DMSO |
| Description | Zanamivir is an influenza viral neuraminidase inhibitor with IC50 values of 0.95 nM and 2.7 nM for influenza A and B, respectively. |
|---|---|
| Related Catalog | |
| Target |
IC50: 0.95 nM (Influenza A); 2.7 nM (Influenza B)[1] |
| In Vitro | Zanamivir interacts with a group of amino acids in the active site of neuraminidase, which are conserved in all influenza A and B strains. Zanamivir blocks the action of neuraminidase, which prevents the cleavage of sialic acid on the cell receptors, thus preventing release and spread of the newly formed virions[2]. |
| In Vivo | Zanamivir has a poor bioavailability in oral administration, with only 4–17% of the agent. Oral delivery of zanamivir has been a problem due to its strong hydrophilic nature that limits its transport across the intestinal epithelium. Permeation enhancers such as sodium cholate, hydroxypropyl β-cyclodextrin could be used with zanamivir to enhance the intestinal permeability[3]. |
| Animal Admin | Rats: Formulations PO-SC (Zanamivir with SC for p.o.) and PO-C (Zanamivir control solution for p.o.) are administered orally at a Zanamivir dose of 10 mg/kg, and IV-R (reference Zanamivir saline solution for i.v.) is administered i.v. at a dose of 1 mg/kg to rats under conscious condition. Blood samples are collected prior to and at 0.5, 1, 2, 3, 4, 6, 8, and 24 hr after administration. At each sampling point, three rats from each group are sacrificed after blood collection to extract the lungs. The lungs are cleansed with saline after extraction of lungs from the rats through a chest incision. The lungs are then transferred into E-tube and stored in the freezer (-80°C) until analysis. Plasma samples are harvested by centrifugation at 1,500 × g for 10 min and stored at -20°C until analysis. The analysis of Zanamivir in both plasma and lungs is performed using before-mentioned LC-MS/MS method[3]. |
| References |
| Density | 1.8±0.1 g/cm3 |
|---|---|
| Melting Point | 256ºC (dec.) |
| Molecular Formula | C12H20N4O7 |
| Molecular Weight | 332.310 |
| Exact Mass | 332.133209 |
| PSA | 198.22000 |
| LogP | -4.13 |
| Index of Refraction | 1.679 |
| Storage condition | 2~8℃ |
| Symbol |
GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H302-H315-H319-H335 |
| Precautionary Statements | P261-P305 + P351 + P338 |
| Hazard Codes | Xn |
| Risk Phrases | 22-36/37/38 |
| Safety Phrases | 26 |
| RIDADR | NONH for all modes of transport |
| RTECS | RA9451000 |
| Precursor 7 | |
|---|---|
| DownStream 0 | |
![methyl (3aR,4R,7aR)-2-methyl-4-(1S,2R,3-triacetoxypropyl)-3a,7a-dihydro-4H-pyrano[3,4-d]oxazole-6-carboxylate structure](https://image.chemsrc.com/caspic/114/78850-37-0.png)
